{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T04:03:59Z","timestamp":1769573039937,"version":"3.49.0"},"reference-count":30,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Breathe"],"accepted":{"date-parts":[[2025,10,22]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Tuberculosis (TB) remains the leading cause of death from a single infectious agent, with 10.8 million cases reported in 2023. While treatment is generally effective, both drug-susceptible (DS-TB) and drug-resistant TB (DR-TB) regimens are associated with adverse events (AEs) that compromise adherence and outcomes. In this viewpoint, we highlight the most clinically relevant AEs: hepatotoxicity, cutaneous reactions and ocular toxicity in DS-TB; and linezolid-associated neuropathy, myelosuppression, QT prolongation and hepatotoxicity in DR-TB. We argue that structured safety monitoring and integration of active TB Drug Safety Monitoring and Management into routine care are critical to improving patient safety. Looking ahead, pharmacogenomics, therapeutic drug monitoring, predictive algorithms and digital health solutions offer opportunities to move from reactive to proactive AE management. By prioritising monitoring, innovation and patient-centred approaches, TB programmes can reduce the burden of AEs, improve adherence and achieve better outcomes.<\/jats:p>","DOI":"10.1183\/20734735.0203-2025","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:50:20Z","timestamp":1769525420000},"page":"250203","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of adverse events in TB care and active TB drug safety monitoring"],"prefix":"10.1183","volume":"22","author":[{"given":"Shamsuddeen Yusuf","family":"Ma'aruf","sequence":"first","affiliation":[]},{"given":"Aparna","family":"Sharma","sequence":"additional","affiliation":[]},{"given":"Shannon","family":"Fox","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2257-3099","authenticated-orcid":false,"given":"Raquel","family":"Duarte","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9691-4741","authenticated-orcid":false,"given":"Christoph","family":"Lange","sequence":"additional","affiliation":[]},{"given":"Simon","family":"Tiberi","sequence":"additional","affiliation":[]}],"member":"81","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"2026012706501177000_22.1.250203.1","unstructured":"World Health Organization . Global tuberculosis report 2024. Geneva, World Health Organization, 2024. https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2024"},{"key":"2026012706501177000_22.1.250203.2","doi-asserted-by":"crossref","first-page":"190","DOI":"10.5588\/ijtld.21.0753","article-title":"Clinical standards for the diagnosis, treatment and prevention of TB infection","volume":"26","author":"Migliori","year":"2022","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026012706501177000_22.1.250203.3","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3390\/medicina61050911","article-title":"The adverse effects of tuberculosis treatment: a comprehensive literature review","volume":"61","author":"Mere\u0161kevi\u010dien\u0117","year":"2025","journal-title":"Medicina (Kaunas)"},{"key":"2026012706501177000_22.1.250203.4","unstructured":"World Health Organization . A practical handbook on the pharmacovigilance of medicines used in the treatment of tuberculosis: enhancing the safety of the TB patient. Geneva, World Health Organization, 2012. www.who.int\/publications\/i\/item\/9789241503495"},{"key":"2026012706501177000_22.1.250203.5","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.3390\/antibiotics12121733","article-title":"How we treat drug-susceptible pulmonary tuberculosis: a practical guide for clinicians","volume":"12","author":"Riccardi","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2026012706501177000_22.1.250203.6","unstructured":"World Health Organization . WHO consolidated guidelines on tuberculosis. Module 4: treatment and care. Geneva, World Health Organization, 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240107243"},{"key":"2026012706501177000_22.1.250203.7","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.23.0078"},{"key":"2026012706501177000_22.1.250203.8","unstructured":"World Health Organization . WHO operational handbook on tuberculosis. Module 4: treatment and care. Geneva, World Health Organization, 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240108141"},{"key":"2026012706501177000_22.1.250203.9","doi-asserted-by":"crossref","unstructured":"Borisov S , Danila E , Maryandyshev A , et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. Eur Respir J 2019; 54: 1901522. doi: 10.1183\/13993003.01522-2019.","DOI":"10.1183\/13993003.01522-2019"},{"key":"2026012706501177000_22.1.250203.10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-024-00504-2","article-title":"Multidrug-resistant tuberculosis","volume":"10","author":"Dheda","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2026012706501177000_22.1.250203.11","first-page":"e20240295","article-title":"Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review","volume":"50","author":"Silva","year":"2025","journal-title":"J Bras Pneumol"},{"key":"2026012706501177000_22.1.250203.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901814"},{"key":"2026012706501177000_22.1.250203.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117166"},{"key":"2026012706501177000_22.1.250203.14","doi-asserted-by":"crossref","first-page":"100533","DOI":"10.1016\/j.jctube.2025.100533","article-title":"Adverse events reported with BPaL and BPaLM regimens in drug-resistant tuberculosis","volume":"40","author":"Sridharan","year":"2025","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"2026012706501177000_22.1.250203.15","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00315-2025"},{"key":"2026012706501177000_22.1.250203.16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/cid\/ciae601","article-title":"The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country multidrug-resistant\/rifampicin-resistant tuberculosis cohort","volume":"81","author":"Khan","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026012706501177000_22.1.250203.17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s12551-022-00929-7","article-title":"Metabolic and electrolyte abnormalities as risk factors in drug-induced long QT syndrome","volume":"14","author":"TeBay","year":"2022","journal-title":"Biophys Rev"},{"key":"2026012706501177000_22.1.250203.18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/cid\/ciae601","article-title":"The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country multidrug-resistant\/rifampicin-resistant tuberculosis cohort","volume":"81","author":"Khan","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026012706501177000_22.1.250203.19","doi-asserted-by":"crossref","first-page":"486","DOI":"10.5588\/ijtldopen.24.0490","article-title":"Updated treatment guidelines for drug-resistant TB: how safe are clofazimine-based regimens?","volume":"1","author":"Pontali","year":"2024","journal-title":"IJTLD Open"},{"key":"2026012706501177000_22.1.250203.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00223-8"},{"key":"2026012706501177000_22.1.250203.21","first-page":"1373","article-title":"Side effects associated with the treatment of multidrug-resistant tuberculosis","volume":"9","author":"T\u00f6r\u00fcn","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026012706501177000_22.1.250203.22","doi-asserted-by":"crossref","first-page":"497","DOI":"10.5588\/ijtldopen.25.0189","article-title":"Analysis of gene expression in patients prior to TB treatment to identify those associated with pyrazinamide-hepatotoxicity","volume":"2","author":"Zielinski","year":"2025","journal-title":"IJTLD Open"},{"key":"2026012706501177000_22.1.250203.23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.20411\/pai.v9i2.705","article-title":"A transcriptomic biomarker predicting linezolid-associated neuropathy during treatment of drug-resistant tuberculosis","volume":"9","author":"Zielinski","year":"2024","journal-title":"Pathog Immun"},{"key":"2026012706501177000_22.1.250203.24","unstructured":"European Centre for Disease Prevention and Control . Training programmes. Date published: 26 April 2022. Date last accessed: 4 September 2025. Date last updated: 28 May 2025. www.ecdc.europa.eu\/en\/training"},{"key":"2026012706501177000_22.1.250203.25","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0283-y"},{"key":"2026012706501177000_22.1.250203.26","first-page":"e62615","article-title":"Nikshay Mitra: a remarkable initiative in efforts against tuberculosis","volume":"16","author":"Yadav","year":"2024","journal-title":"Cureus"},{"key":"2026012706501177000_22.1.250203.27","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3390\/antibiotics12050811","article-title":"Safety profile of medicines used for the treatment of drug-resistant tuberculosis: a descriptive study based on the WHO database (VigiBase)","volume":"12","author":"Duga","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2026012706501177000_22.1.250203.28","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1164\/rccm.202103-0564OC","article-title":"A rapid pharmacogenomic assay to detect NAT2 polymorphisms and guide isoniazid dosing for tuberculosis treatment","volume":"204","author":"Verma","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012706501177000_22.1.250203.29","doi-asserted-by":"publisher","DOI":"10.1086\/430441"},{"key":"2026012706501177000_22.1.250203.30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12879-025-10609-y","article-title":"Prediction of tuberculosis treatment outcomes using biochemical makers with machine learning","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Infect Dis"}],"container-title":["Breathe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/20734735.0203-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:50:22Z","timestamp":1769525422000},"score":1,"resource":{"primary":{"URL":"http:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/20734735.0203-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,27]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1183\/20734735.0203-2025"],"URL":"https:\/\/doi.org\/10.1183\/20734735.0203-2025","relation":{},"ISSN":["1810-6838","2073-4735"],"issn-type":[{"value":"1810-6838","type":"print"},{"value":"2073-4735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}